Loading [MathJax]/extensions/tex2jax.js

A patent review of MALT1 inhibitors (2013-present)

Research output: Contribution to journalReview articleResearchpeer review

Authors

External Research Organisations

  • Helmholtz Zentrum München - German Research Center for Environmental Health
Plum Print visual indicator of research metrics
  • Citations
    • Citation Indexes: 20
    • Patent Family Citations: 6
  • Captures
    • Readers: 21
  • Mentions
    • References: 2
  • Social Media
    • Shares, Likes & Comments: 17
see details

Details

Original languageEnglish
Pages (from-to)1079-1096
Number of pages18
JournalExpert Opinion on Therapeutic Patents
Volume31
Issue number12
Early online date15 Jul 2021
Publication statusPublished - 2021

Abstract

Introduction: MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulatory target for the treatment of autoimmune/inflammatory diseases. Further, chronic MALT1 protease activation drives survival of lymphomas, suggesting that MALT1 is a suitable drug target for lymphoid malignancies. Recent studies have indicated that MALT1 inhibition impairs immune suppressive function of regulatory T cells in the tumor microenvironment, suggesting that MALT1 inhibitors may boost anti-tumor immunity in the treatment of solid cancers. Areas covered: This review summarizes the literature on MALT1 patents and applications. We discuss the potential therapeutic uses for MALT1 inhibitors based on patents and scientific literature. Expert opinion: There has been a steep increase in MALT1 inhibitor patents. Compounds with high selectivity and good bioavailability have been developed. An allosteric binding pocket is the preferred site for potent and selective MALT1 targeting. MALT1 inhibitors have moved to early clinical trials, but toxicological studies indicate that long-term MALT1 inhibition can disrupt immune homeostasis and lead to autoimmunity. Even though this poses risks, preventing immune suppression may favor the use of MALT1 inhibitors in cancer immunotherapies.

Keywords

    allosteric inhibition, autoimmunity, cancer immunotherapy, lymphoma, MALT1, proteases, regulatory T cells

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

A patent review of MALT1 inhibitors (2013-present). / Hamp, Isabel; O’Neill, Thomas J.; Plettenburg, Oliver et al.
In: Expert Opinion on Therapeutic Patents, Vol. 31, No. 12, 2021, p. 1079-1096.

Research output: Contribution to journalReview articleResearchpeer review

Hamp I, O’Neill TJ, Plettenburg O, Krappmann D. A patent review of MALT1 inhibitors (2013-present). Expert Opinion on Therapeutic Patents. 2021;31(12):1079-1096. Epub 2021 Jul 15. doi: 10.1080/13543776.2021.1951703
Hamp, Isabel ; O’Neill, Thomas J. ; Plettenburg, Oliver et al. / A patent review of MALT1 inhibitors (2013-present). In: Expert Opinion on Therapeutic Patents. 2021 ; Vol. 31, No. 12. pp. 1079-1096.
Download
@article{9e692bb122574ddaa31a72e0e6f82111,
title = "A patent review of MALT1 inhibitors (2013-present)",
abstract = "Introduction: MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulatory target for the treatment of autoimmune/inflammatory diseases. Further, chronic MALT1 protease activation drives survival of lymphomas, suggesting that MALT1 is a suitable drug target for lymphoid malignancies. Recent studies have indicated that MALT1 inhibition impairs immune suppressive function of regulatory T cells in the tumor microenvironment, suggesting that MALT1 inhibitors may boost anti-tumor immunity in the treatment of solid cancers. Areas covered: This review summarizes the literature on MALT1 patents and applications. We discuss the potential therapeutic uses for MALT1 inhibitors based on patents and scientific literature. Expert opinion: There has been a steep increase in MALT1 inhibitor patents. Compounds with high selectivity and good bioavailability have been developed. An allosteric binding pocket is the preferred site for potent and selective MALT1 targeting. MALT1 inhibitors have moved to early clinical trials, but toxicological studies indicate that long-term MALT1 inhibition can disrupt immune homeostasis and lead to autoimmunity. Even though this poses risks, preventing immune suppression may favor the use of MALT1 inhibitors in cancer immunotherapies.",
keywords = "allosteric inhibition, autoimmunity, cancer immunotherapy, lymphoma, MALT1, proteases, regulatory T cells",
author = "Isabel Hamp and O{\textquoteright}Neill, {Thomas J.} and Oliver Plettenburg and Daniel Krappmann",
note = "Funding Information: This paper has been funded by the Deutsche Forschungsgemeinschaft SFB 1054 project A04 to DK. Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
doi = "10.1080/13543776.2021.1951703",
language = "English",
volume = "31",
pages = "1079--1096",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Current Patents, Ltd.",
number = "12",

}

Download

TY - JOUR

T1 - A patent review of MALT1 inhibitors (2013-present)

AU - Hamp, Isabel

AU - O’Neill, Thomas J.

AU - Plettenburg, Oliver

AU - Krappmann, Daniel

N1 - Funding Information: This paper has been funded by the Deutsche Forschungsgemeinschaft SFB 1054 project A04 to DK. Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

N2 - Introduction: MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulatory target for the treatment of autoimmune/inflammatory diseases. Further, chronic MALT1 protease activation drives survival of lymphomas, suggesting that MALT1 is a suitable drug target for lymphoid malignancies. Recent studies have indicated that MALT1 inhibition impairs immune suppressive function of regulatory T cells in the tumor microenvironment, suggesting that MALT1 inhibitors may boost anti-tumor immunity in the treatment of solid cancers. Areas covered: This review summarizes the literature on MALT1 patents and applications. We discuss the potential therapeutic uses for MALT1 inhibitors based on patents and scientific literature. Expert opinion: There has been a steep increase in MALT1 inhibitor patents. Compounds with high selectivity and good bioavailability have been developed. An allosteric binding pocket is the preferred site for potent and selective MALT1 targeting. MALT1 inhibitors have moved to early clinical trials, but toxicological studies indicate that long-term MALT1 inhibition can disrupt immune homeostasis and lead to autoimmunity. Even though this poses risks, preventing immune suppression may favor the use of MALT1 inhibitors in cancer immunotherapies.

AB - Introduction: MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulatory target for the treatment of autoimmune/inflammatory diseases. Further, chronic MALT1 protease activation drives survival of lymphomas, suggesting that MALT1 is a suitable drug target for lymphoid malignancies. Recent studies have indicated that MALT1 inhibition impairs immune suppressive function of regulatory T cells in the tumor microenvironment, suggesting that MALT1 inhibitors may boost anti-tumor immunity in the treatment of solid cancers. Areas covered: This review summarizes the literature on MALT1 patents and applications. We discuss the potential therapeutic uses for MALT1 inhibitors based on patents and scientific literature. Expert opinion: There has been a steep increase in MALT1 inhibitor patents. Compounds with high selectivity and good bioavailability have been developed. An allosteric binding pocket is the preferred site for potent and selective MALT1 targeting. MALT1 inhibitors have moved to early clinical trials, but toxicological studies indicate that long-term MALT1 inhibition can disrupt immune homeostasis and lead to autoimmunity. Even though this poses risks, preventing immune suppression may favor the use of MALT1 inhibitors in cancer immunotherapies.

KW - allosteric inhibition

KW - autoimmunity

KW - cancer immunotherapy

KW - lymphoma

KW - MALT1

KW - proteases

KW - regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=85110810359&partnerID=8YFLogxK

U2 - 10.1080/13543776.2021.1951703

DO - 10.1080/13543776.2021.1951703

M3 - Review article

C2 - 34214002

AN - SCOPUS:85110810359

VL - 31

SP - 1079

EP - 1096

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 12

ER -

By the same author(s)